Proton pump inhibitor use and association with spontaneous bacterial peritonitis in patients with cirrhosis and ascites;L'utilisation des inhibiteurs de la pompe à protons chez les patients cirrhotiques présentant une ascite

Annals of Pharmacotherapy

Volumn 46, Issue 10, 2012, Pages 1413-1418

  Siple, Jolene F ^a   Morey, Jessica M ^a   Gutman, Tracy E ^a   Weinberg, Kathy L ^a   Collins, Peggie D ^a  

^a PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Ascites; Cirrhosis; Clostridium difficile; Proton pump inhibitor; Spontaneous bacterial peritonitis

Indexed keywords

PROTON PUMP INHIBITOR;

ANTIBIOTIC THERAPY; ARTICLE; ASCITES; BACTERIAL PERITONITIS; CASE CONTROL STUDY; CLOSTRIDIUM DIFFICILE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS VARICES; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION RISK; LIVER CIRRHOSIS; MEDICAL LITERATURE; MEDLINE; META ANALYSIS (TOPIC); PORTAL HYPERTENSION; PRIORITY JOURNAL; STOMACH PH;

ASCITES; BACTERIAL INFECTIONS; FIBROSIS; HUMANS; PERITONITIS; PROTON PUMP INHIBITORS;

EID: 84867794085     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R174     Document Type: Article

References (29)

1. Sease JM, Timm EG, Stragand JJ. Portal hypertension and cirrhosis. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. 7th ed. Boston: Mc-Graw-Hill, 2008:633-49.
2. Martell M, Coll M, Ezkurdia N, Raurell I, Genesca J. Physiopathology of splanchnic vasodilation in portal hypertension. World J Hepatol 2010;2: 208-20.
3. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med 2004;350:1646-54.
4. Lodato F, Azzaroli F, Girolamo M, et al. Proton pump inhibitors in cir-rhosis: tradition or evidence based practice? World J Gastroenterol 2008; 14:2980-5.
5. Garcia-Saenz-de-Sicilia M, Sanchez-Avila F, Chavez-Tapia NC, et al. PPIs are not associated with a lower incidence of portal-hypertension-re-lated bleeding in cirrhosis. W J Gastroenterol 2010;15:5869-73.
6. Alaniz C. Management of cirrhotic ascites. Clin Pharm 1989;8:645-54.
7. Heil T, Mattes P, Loeprecht H. Gastro-oesophageal reflux: an aetiologi-cal factor for bleeding in oesophageal varices? Br J Surg 1980;67:467-8.
8. Bauer TM, Steinbruckner B, Brinkmann FE, et al. Small intestinal bacte-rial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol 2001;96:2962-7.
9. Bajaj J, Zadvornova Y, Heuman D, et al. Association of proton pump in-hibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 2009;104:1130-4.
10. Goel GA, Deshpande A, Lopez R, Hall GS, Van Duin D, Carey WD. In-creased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. Clin Gastroenterol Hepatol 2012;10:422-7.
11. Bulsiewicz WJ, Scherer JR, Feinglass JM, Howden CWA, Flamm SL. Proton pump inhibitor use is independently associated with spontaneous bacterial peritonitis in cirrhotics with ascites (abstract 63). Gastroenterol-ogy 2009;136(suppl):A-11.
12. Campbell MS, Obstein K, Reddy KR, Yang Y-X. Association between proton pump inhibitor use and spontaneous bacterial peritonitis. Dig Dis Sci 2008;53:394-8.
13. Trikudanathan G, Israel J, Cappa J, O'Sullivan DM. Association between protein pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients-a systematic review and meta-analysis. Int J Clin Pract 2011; 66:674-8.
14. Choi EJ, Lee HJ, Kim KO, et al. Association between acid suppressive therapy and spontaneous bacterial peritonitis in cirrhotic patients with as-cites. Scand J Gastroenterol 2011;46:616-20.
15. Islam S, Islam EA, Frandah W, et al. Spontaneous bacterial peritonitis and proton pump inhibitors: correlation of disease process? (abstract 1339). Gastroenterology 2011;140(suppl):S461-2.
16. Northup PG, Argo CK, Berg CL. Chronic proton pump inhibitor use is strongly associated with hepatorenal syndrome and spontaneous bacterial peritonitis in cirrhosis patients (abstract 38). Hepatology 2008;48:325.
17. Bajaj JS, Ananthakrishnam AN, Hafeezullah M, et al. Clostridium diffi-cile is associated with poor outcomes in patients with cirrhosis: a national and tertiary center perspective. Am J Gastroenterol 2010;105:106-13.
18. Wiest R, Krag A, Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut 2012;61:297-310.
19. Caruntu FA, Benea L. Spontaneous bacterial peritonitis: pathogenesis, di-agnosis, treatment. J Gastrointest Liver Dis 2006;15:51-56.
20. Sheer T, Runyon BA. Spontaneous bacterial peritonitis. Dig Dis 2005; 23:39-46.
21. McCarthy DM. Adverse effects of proton pump inhibitor drugs: clues and conclusions. Curr Opin Gastroenterol 2010;26:624-31.
22. US Food and Drug Administration: Proton pump inhibitors (PPIs)-drug safety communication: Clostridium difficile-associated diarrhea (CDAD) can be associated with stomach acid drugs. Posted February 8, 2012. www.fda.gov/Drugs/DrugSafety/ucm290510.htm (accessed 2012 Feb 9).
23. Goel GA, Deshpande A, Lopez R, Hall GS, Van Duin D, Carey WD. Proton pump inhibitor use is associated with spontaneous bacterial peri-tonitis in cirrhosis (abstract 1915). Gastroenterology 2010;138(suppl): S816.
24. Musa S, Moran C, Rahman T. Clostridium difficile infection and liver disease. J Gastrointestinal Liver Dis 2010;19:303-10.
25. Dial S, Delaney JAC, Barkun AN, Suissa S. Use of gastric acid suppres-sive agents and the risk of community acquired Clostridium difficile-as-sociated disease. JAMA 2005;294:2989-95.
26. Talley NJ. Risks of proton-pump inhibitors: what every doctor should know. Med J Aust 2009;190:109-10.
27. Katz MH. Failing the acid test. Benefits of proton pump inhibitors may not justify the risks for many users. Arch Intern Med 2010;170:747-8.
28. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. AASLD 2007 Guidelines. Hepatology 2007;46: 922-38.
29. 2010 US spending and prescription information. IMS Health, April 7, 2011. www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Top_Line_Data/2010_Top_Therapeutic_Classes_by_Sales.pdf (ac-cessed 2011 Dec 18).